XML 27 R15.htm IDEA: XBRL DOCUMENT
v3.21.1

Financing | 3 Months Ended
--- | ---
Apr. 02, 2021
Debt Disclosure [Abstract] |
Financing | FINANCING As of April 2, 2021, the Company was in compliance with all of its debt covenants. The components of the Company’s debt were as follows ($ in millions):
| April 2, 2021 |  | December 31, 2020
Euro-denominated commercial paper (€500 million) | $ | 588 |  |  | $ | 611 |
Zero-coupon LYONs due 2021 | — |  |  | 24 |
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”) | — |  |  | 290 |
Floating rate senior unsecured notes due 2022 (€250 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”) | 294 |  |  | 305 |
2.05% senior notes due 2022 (the “2022 Biopharma Notes”) | 698 |  |  | 698 |
0.5% senior unsecured bonds due 2023 (CHF 540 million aggregate principal amount) (the “2023 CHF Bonds”) | 574 |  |  | 611 |
1.7% senior unsecured notes due 2024 (€900 million aggregate principal amount) (the “2024 Euronotes”) | 1,054 |  |  | 1,096 |
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”) | 697 |  |  | 697 |
2.5% senior unsecured notes due 2025 (€800 million aggregate principal amount) (the “2025 Euronotes”) | 938 |  |  | 975 |
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”) | 498 |  |  | 498 |
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”) | 1,462 |  |  | 1,520 |
2.1% senior unsecured notes due 2026 (€800 million aggregate principal amount) (the “2026 Euronotes”) | 937 |  |  | 975 |
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”) | 278 |  |  | 297 |
1.2% senior unsecured notes due 2027 (€600 million aggregate principal amount) (the “2027 Euronotes”) | 702 |  |  | 729 |
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”) | 1,460 |  |  | 1,518 |
1.125% senior unsecured bonds due 2028 (CHF 210 million aggregate principal amount) (the “2028 CHF Bonds”) | 226 |  |  | 241 |
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”) | 795 |  |  | 795 |
2.5% senior unsecured notes due 2030 (€800 million aggregate principal amount) (the “2030 Euronotes”) | 941 |  |  | 978 |
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”) | 2,046 |  |  | 2,127 |
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”) | 479 |  |  | 514 |
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”) | 1,453 |  |  | 1,511 |
3.25% senior unsecured notes due 2029 (the “2039 Biopharma Notes”) | 889 |  |  | 889 |
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”) | 499 |  |  | 499 |
1.8% senior unsecured notes due 2049 (€750 million aggregate principal amount) (the “2049 Biopharma Euronotes”) | 872 |  |  | 907 |
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”) | 889 |  |  | 889 |
2.6% senior unsecured notes due 2050 (the “2050 U.S. Notes”) | 979 |  |  | 979 |
Other | 29 |  |  | 31 |
Total debt | 20,277 |  |  | 21,204 |
Less: currently payable | 10 |  |  | 11 |
Long-term debt | $ | 20,267 |  |  | $ | 21,193 |
For additional details regarding the Company’s debt financing, refer to Note 11 of the Company’s financial statements as of and for the year ended December 31, 2020 included in the Company’s 2020 Annual Report. The Company has historically satisfied any short-term liquidity needs that are not met through operating cash flow and available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper programs. The Company’s $5.0 billion u nsecured, multi-year revolving credit facility with a syndicate of banks that expires on August 24, 2024 (the “Five-Year Facility”), is available for direct borrowings and provides support for the commercial programs. As of April 2, 2021, borrowings outstanding under the Company’s euro-denominated commercial paper program had a weighted average annual interest rate of negative 0.4% and a weighted average remaining maturity of approximately 24 days. Debt discounts, premiums and debt issuance costs totaled $127 million and $132 million as of April 2, 2021 and December 31, 2020, respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above. Credit Facilities For a description of the Five-Year Facility, refer to the Company’s 2020 Annual Report. Guarantors of Debt The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned subsidiaries. The Floating Rate 2022 Euronotes, 2025 Euronotes, 2027 Euronotes and euro-denominated commercial paper were issued by DH Europe Finance S.A. (“Danaher International”). The 2022 Biopharma Notes, 2024 Biopharma Notes, 2026 Biopharma Euronotes, 2028 Biopharma Euronotes, 2029 Biopharma Notes, 2031 Biopharma Euronotes, 2039 Biopharma Euronotes, 2039 Biopharma Notes, 2049 Biopharma Euronotes, 2049 Biopharma Notes and euro-denominated commercial paper were issued by DH Europe Finance II S.a.r.l. (“Danaher International II”). The 2023 CHF Bonds and 2028 CHF Bonds were issued by DH Switzerland Finance S.A. (“Danaher Switzerland”). The 2021 Yen Notes, 2027 Yen Notes and 2032 Yen Notes were issued by DH Japan Finance S.A. (“Danaher Japan”). Each of Danaher International, Danaher International II, Danaher Switzerland and Danaher Japan are wholly-owned finance subsidiaries of Danaher Corporation. All of the outstanding and future securities issued by each of these entities are or will be fully and unconditionally guaranteed by the Company and these guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness. LYONs Redemption During the first quarter of 2021, holders of certain of the Company’s LYONs converted such LYONs into an aggregate of 912 thousand shares of the Company’s common stock, par value $0.01 per share. The Company’s deferred tax liability of $10 million associated with the book and tax basis difference in converted LYONs was transferred to additional paid-in capital. The residual LYONS not converted into shares of the Company’s common stock were redeemed at face value on January 22, 2021.

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -URI http://asc.fasb.org/topic&trid=2208564 + Details
Name: | us-gaap_DebtDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration